PremiumCompany AnnouncementsSpero Therapeutics’ Phase 3 Trial Meets Primary Endpoint GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint PremiumCompany AnnouncementsSpero Therapeutics Reports 2024 Financial Results and Updates Spero Therapeutics reports Q4 EPS (38c), consensus (31c) SPRO Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlySpero Therapeutics downgraded at Evercore on lack of capital allocation clarity Spero Therapeutics downgraded to In Line from Outperform at Evercore ISI Spero Therapeutics downgraded to Hold from Buy at TD Cowen